logo
Boom Supersonic's XB-1 Civilian Jet Crosses the Speed of Sound

Boom Supersonic's XB-1 Civilian Jet Crosses the Speed of Sound

Yahoo29-01-2025

Boom Supersonic hit a milestone yesterday when its XB-1 experimental jet passed Mach 1.0, the speed of sound, on its way to Mach 1.122 or 860.87 mph. The event took place over the Mohave Desert, the same location where Chuck Yeager broke the sound barrier for the first time in 1947. Yesterday's flight was number 11 of the XB-1 human-piloted test flights that started last March.
And the test also the culmination of years of work for Boom, which began operations in 2014 and, against much industry skepticism, has become the first U.S. independent company to join the supersonic club. The last civil supersonic jet was the Concorde, which flew from 1969 through 2003.
More from Robb Report
This New Supersonic Jet Can Fly From London to N.Y.C. in Under 2 Hours
Forget Top Gun. Here's What It's Like to Fly an Experimental Supersonic Jet
Amid Current 'Uncertainty,' the Private Jet Market Is Expected to Remain Strong in the Long Term
'XB-1's supersonic flight demonstrates that the technology for passenger supersonic flight has arrived,' said Boom's founder Blake Scholl. 'A small band of talented and dedicated engineers has accomplished what previously took governments and billions of dollars.' Boom has not received grants from any U.S. military programs, which some competitors considered essential to get a supersonic program off the ground.
Tristan 'Geppetto' Brandenburg, Boom's chief test pilot and a former Navy test pilot, made the flight yesterday. It followed a protocol that expanded its flight envelope through subsonic, transonic, and then supersonic speeds. It was shadowed by two former fighter jets that Boom uses to monitor the XB-1 during the test flights.
Scholl said the next step is to scale up the technology used on the XB-1 for Boom's supersonic airliner called the Overture. 'Our ultimate goal is to bring the benefits of supersonic flight to everyone,' he said.
The Overture is a much larger, more complicated commercial aircraft, designed to fly at Mach 1.7 and carry 64 to 80 passengers. Boom anticipates that the first commercial Overtures will take flight in 2029. It has begun construction of a production facility in North Carolina and has received 130 orders and pre-orders from American Airlines, United Airlines and Japan Airlines.
Boom says, at scale, it should be able to produce 66 Overtures per year. But that is still just a business plan that many aviation experts believe is unrealistic, citing the fact that the company was forced to build its own supersonic engines after major aviation engine manufacturers turned down the project.
Still, the company proved that it has reached the first step through an experimental jet—a step that its better-funded competitor, Aerion, never reached aft 20 years of developing its own supersonic business jet concept. It abruptly shut down in May 2021, citing little investor appetite in the supersonic concept.
As a test platform, the XB-1 tries out multiple technologies that will be applied to the much larger and more complicated Overture. They include an augmented-reality vision system, which aids the pilot in seeing the runway on takeoff and landing, and digitally optimized aerodynamics, referring to the shape of the airframe and wings for the greatest stability at supersonic speeds. The aircraft is almost entirely made from carbon-composite materials, which allowed the designers to shape it more precisely.
The company will continue testing the XB-1 going forward.
Best of Robb Report
The 2024 Chevy C8 Corvette: Everything We Know About the Powerful Mid-Engine Beast
The World's Best Superyacht Shipyards
The ABCs of Chartering a Yacht
Click here to read the full article.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CNOOC starts oil production at South China Sea field
CNOOC starts oil production at South China Sea field

Yahoo

timean hour ago

  • Yahoo

CNOOC starts oil production at South China Sea field

China National Offshore Oil Corporation (CNOOC) has commenced production at the Weizhou 5-3 oilfield development project in the Beibu Gulf Basin of the South China Sea. With an average water depth of around 35m, the project is expected to reach peak production of approximately 10,000 barrels of oil equivalent per day (boepd) by 2026. The Weizhou 5-3 Oilfield utilises one self-installing wellhead platform and uses nearby existing facilities for its development. The production plan includes the commissioning of ten development wells, consisting of seven production wells, two water injection wells and one gas injection well. CNOOC owns a 51% interest in the Weizhou 5-3 oilfield, while Smart Oil Investment holds the remaining 49% stake. CNOOC is reputed to be the largest producer of offshore crude oil and natural gas in China and one of the largest independent oil and gas exploration and production companies globally. The company focuses mainly on the exploration, development, production and sale of crude oil and natural gas. In China, CNOOC carries out oil and gas exploration and development primarily via independent operations and cooperation projects. The company has been increasing its reserves and production mainly through independent exploration and exploitation. As of the end of 2024, around 88.7% of net proved reserves and 85.1% of net production in China were from the company's self-operated oil and gas fields. In April, CNOOC commenced production at the Wenchang 9-7 Oilfield Development Project in the western Pearl River Mouth Basin. Furthermore, in March, production began at two additional projects: the Caofeidian 6-4 Oilfield Comprehensive Adjustment project and the Wenchang 19-1 oilfield phase two project. "CNOOC starts oil production at South China Sea field" was originally created and published by Offshore Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

Why Recursion Pharmaceuticals (RXRX) Soared On Friday
Why Recursion Pharmaceuticals (RXRX) Soared On Friday

Yahoo

time2 days ago

  • Yahoo

Why Recursion Pharmaceuticals (RXRX) Soared On Friday

We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Why Recursion Pharmaceuticals (RXRX) Soared On Friday
Why Recursion Pharmaceuticals (RXRX) Soared On Friday

Yahoo

time2 days ago

  • Yahoo

Why Recursion Pharmaceuticals (RXRX) Soared On Friday

We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store